Vol. 11 No. 1 (2015): January/February

Articles

• Letter from the Editor, Publisher

  Richard A. DeVito, Jr, Paul Alexander Sloan, MD

  • PDF

• Using urine drug testing to support healthy boundaries in clinical care

  Howard A. Heit, MD, FACP, FASAM, Douglas L. Gourlay, MD, MSc, FRCPC, FASAM

  • Requires Subscription or Fee PDF (USD 56)

• Immunoassay in healthcare testing applications

  Anne Z. DePriest, PharmD, BCPS, David L. Black, PhD, D-ABFT, Timothy A. Robert, PhD, D-ABCC

  • Requires Subscription or Fee PDF (USD 56)

• A primer on definitive gas and liquid chromatography drug testing: What clinicians need to know

  Amadeo Pesce, PhD, Kenneth L. Kirsh, PhD, Angela Huskey, PharmD, CPE, Steven D. Passik, PhD, Catherine A. Hammett-Stabler, PhD

  • Requires Subscription or Fee PDF (USD 56)

• Choosing the right laboratory: A review of clinical and forensic toxicology services for urine drug testing in pain management

  Gary M. Reisfield, MD, Bruce A. Goldberger, PhD, Roger L. Bertholf, PhD

  • Requires Subscription or Fee PDF (USD 56)

• Treatment changes following aberrant urine drug test results for patients prescribed chronic opioid therapy

  Benjamin J. Morasco, PhD, Erin E. Krebs, MD, MPH, Renee Cavanagh, MS, Stephanie Hyde, MA, Aysha Crain, MSW, Steven K. Dobscha, MD

  • Requires Subscription or Fee PDF (USD 56)

• Specimen validity testing in urine drug monitoring of medications and illicit drugs: Clinical implications

  Kenneth L. Kirsh, PhD, Paul J. Christo, MD, MBA, Howard Heit, MD, Katherine Steffel, PharmD, Steven D. Passik, PhD

  • Requires Subscription or Fee PDF (USD 56)

• Trends in drug use from urine drug testing of addiction treatment clients

  Kenneth L. Kirsh, PhD, Howard A. Heit, MD, Angela Huskey, PharmD, CPE, Jennifer Strickland, PharmD, BCPS, Kathleen Egan City, MA, BSN, RN, Steven D. Passik, PhD

  • Requires Subscription or Fee PDF (USD 56)

• Drug testing and adherence monitoring in pain management: Oral fluid testing

  Christine Moore, PhD, DSc, DABCC

  • Requires Subscription or Fee PDF (USD 56)

• FDA/DEA/PDMP/UDT: Alphabet soup or sensible and integrated risk management?

  Steven D. Passik, PhD, Kenneth L. Kirsh, PhD, Robert K. Twillman, PhD

  • Requires Subscription or Fee PDF (USD 56)

• Medication monitoring and drug testing ethics project

  Richard Payne, MD, Jeffrey L. Moe, PhD, Catherine Harvey Sevier, DrPH, David Sevier, MS, Michael Waitzkin, JD, LLM

  • Requires Subscription or Fee PDF (USD 56)

• Evaluating motives: Two simple tests to identify and avoid entanglement in legally dubious urine drug testing schemes

  Michael C. Barnes, Esq., Stacey L. Worthy, Esq

  • Requires Subscription or Fee PDF (USD 56)